EN
中文
EN
Who We Are
Newsroom
Innovation
Products
Investor Relations
Careers
Contact Us
Information Disclosure
Home
>
Investor Relations
>
Information Disclosure
H Share
NOTICE OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING
TERMS OF REFERENCE FOR THE REMUNERATION AND ASSESSMENT COMMITTEE OF THE BOARD
TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE OF THE BOARD
TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND RULES OF PROCEDURES
VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR RECOMBINANT POLIOMYELITIS VACCINE
Letter to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
Letter to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
Monthly Return of Equity Issuer on Movements in Securities
VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR ABSORBED TETANUS VACCINE
1
4
5
6
7
8
44